Pulpitis
Conditions
Interventions
This is a randomized placebo-controlled clinical trial, where pain levels on a scale of 0 - 100 will be assessed during the endodontic treatment procedure in patients diagnosed with symptomatic irreve
E02.331
Sponsors
Faculdade de Odontologia de Bauru - Universidade de São Paulo
Faculdade de Odontologia de Bauru - Universidade de São Paulo
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Clinical diagnosis of unilateral symptomatic irreversible pulpitis in mandibular premolars and molars
Exclusion criteria
Exclusion criteria: Allergy to ketorolac or the anesthetic used; history or presence of uncontrolled systemic diseases; chronic pain; neurological; hormonal; rheumatic; psychiatric disorders; pregnancy; lactation; pacemaker presence
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1: It is expected to find improvement in analgesic efficacy and, therefore, to improve anesthesia of the inferior alveolar nerve during irreversible pulpitis therapy with a significance level of 5%.;Outcome found 1: It was observed that there was a 35% improvement in the analgesic efficacy of the inferior alveolar nerve block in the comparison between the active and placebo groups. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 2: An improvement in pain intensity is expected after the use of ketorolac 10mg, with a significance level of 5%.;Outcome found 2: It was observed that after using the drug ketorolac 10mg there was no statistical difference between the groups, but with an improvement in the level of pain of 75% on average, when compared to before and after using the drug. | — |
Countries
Brazil
Contacts
Public ContactRenan Furlan
Faculdade de Odontologia de Bauru - SP
Outcome results
None listed